Geron shares are trading higher after the company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Portfolio Pulse from Benzinga Newsdesk
Geron's stock price increased following the announcement that the FDA Oncologic Drugs Advisory Committee voted in favor of imetelstat's clinical benefit/risk profile for treating transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
March 14, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's stock price is likely to experience a short-term increase following the positive FDA committee vote on imetelstat for treating transfusion-dependent anemia in certain myelodysplastic syndromes.
The FDA committee's favorable vote on imetelstat directly impacts Geron's market perception and potential future revenues, making this news highly relevant and important for investors. The positive outcome is likely to boost investor confidence in Geron's pipeline, leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100